SEARCH

SEARCH BY CITATION

References

  • Ali A, Dua Y, Constance JE, Franklin MR, Dudek FE. (2012) A once-per-day, drug-in-food protocol for prolonged administration of antiepileptic drugs in animal models. Epilepsia 53:199206.
  • Auvin S, Pineda E, Shin D, Gressens P, Mazarati A. (2012) Novel animal models of pediatric epilepsy. Neurotherapeutics 9:245261.
  • Brooks-Kayal AR, Bath KG, Berg AT, Galanopoulou AS, Holmes GL, Jensen FE, Kanner AM, O'Brien TJ, Patel M, Scharfman H, Whittemore VH, Winawer MR, Patel M, Scharfman HE. (2013) Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy. Epilepsia 54(Suppl. 4): 4460.
  • Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH, STAIR Group (2009). Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40:22442250.
  • Fisher RS, Blum DE, DiVentura B, Vannest J, Hixson JD, Moss R, Herman ST, Fureman BE, French JA. (2012) Seizure diaries for clinical research and practice: limitations and future prospects. Epilepsy Behav 24:304310.
  • Galanopoulou AS. (2013) Basic mechanisms of catastrophic epilepsy – Overview from animal models. Brain Dev Jan 10 [Epub ahead of print].
  • Galanopoulou AS, Buckmaster PS, Staley KJ, Moshé SL, Perucca E, Engel J Jr, Löscher W, Noebels JL, Pitkänen A, Stables J, White HS, O'Brien TJ, Simonato M, American Epilepsy Society Basic Science Committee And The International League Against Epilepsy Working Group On Recommendations For Preclinical Epilepsy Drug Discovery. (2012) Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 53:571582.
  • Galanopoulou AS, Kokaia M, Loeb JA, Nehlig A, Pitkänen A, Rogawski MA, Staley KJ, Whittemore VH, Dudek FE. (2013) Epilepsy therapy development: Technical and methodological issues in studies with animal models. Epilepsia 54(Suppl. 4): 1323.
  • Geerts A, Brouwer O, Stroink H, van Donselaar C, Peters B, Peeters E, Arts WF. (2012) Onset of intractability and its course over time: the Dutch study of epilepsy in childhood. Epilepsia 53:741751.
  • Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8:e1000412.
  • Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT III, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD. (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490:187191.
  • Löscher W. (2007) The pharmacokinetics of antiepileptic drugs in rats: consequences for maintaining effective drug levels during prolonged drug administration in rat models of epilepsy. Epilepsia 48:12451258.
  • Löscher W, Brandt C. (2010) Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev 62:668700.
  • Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler JP, Mead R, Niessen HG, Petri S, Pradat PF, Robberecht W, Ruegg M, Schwalenstöcker B, Stiller D, van den Berg L, Vieira F, von Horsten S. (2010) Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler 11:3845.
  • Mani R, Pollard J, Dichter MA. (2011) Human clinical trails in antiepileptogenesis. Neurosci Lett 497:251256.
  • Muhlhausler BS, Bloomfield FH, Gillman MW. (2013) Whole animal experiments should be more like human randomized controlled trials. PLoS Biol 11:e1001481.
  • O'Collins VE, Macleod MR, Donnan GA, Howells DW. (2012) Evaluation of combination therapy in animal models of cerebral ischemia. J Cereb Blood Flow Metab 32:585597.
  • Philip M, Benatar M, Fisher M, Savitz SI. (2009) Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke 40:577581.
  • Pitkänen A. (2010) Therapeutic approaches to epileptogenesis–hope on the horizon. Epilepsia 51(Suppl. 3):217.
  • Pitkänen A, Lukasiuk K. (2011) Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 10:173186.
  • Schmidt D. (2012) Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. Epileptic Disord 14:105113.
  • Schmidt D, Sillanpää M. (2012) Evidence-based review on the natural history of the epilepsies. Curr Opin Neurol 25:159163.
  • Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, Lincecum J, Leblanc GG, Lee LB, Luo F, Morgan D, Morse I, Refolo LM, Riddell DR, Scearce-Levie K, Sweeney P, Yrjänheikki J, Fillit HM. (2011) Accelerating drug discovery for Alzheimer's disease: Best practices for preclinical animal studies. Alzheimers Res Ther 28:2840.
  • Sloviter RS, Bumanglag AV. (2013) Defining “epileptogenesis” and identifying “antiepileptogenic targets” in animal models of acquired temporal lobe epilepsy is not as simple as it might seem. Neuropharmacology, 69:315.
  • Steward O, Popovich PG, Dietrich WD, Kleitman N. (2012) Replication and reproducibility in spinal cord injury research. Exp Neurol 233:597605.